ibutilide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


123»
  • ||||||||||  Multaq (dronedarone) / Sanofi, Corvert (ibutilide) / Pfizer, Brinavess (vernakalant) / Merck (MSD), Correvio
    Review, Journal:  Effect of Obesity on the Use of Antiarrhythmics in Adults With Atrial Fibrillation: A Narrative Review. (Pubmed Central) -  Aug 22, 2024   
    This observation is based on heterogeneous studies of participants with an average BMI and poorly controlled confounding factors such as multimorbidity, concomitant medications, varying routes of administration, and assessment of obesity. Controlled trials with stratification at the time of recruitment for obesity are necessary to determine the significance of these findings.
  • ||||||||||  Corvert (ibutilide) / Pfizer, Brinavess (vernakalant) / Merck (MSD), Correvio
    Clinical, Retrospective data, Review, Journal:  External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis. (Pubmed Central) -  Jun 3, 2024   
    Despite the low quality of evidence, this systematic review provides important information on electrical and pharmacological strategies to help patients and physicians deal with AF and atrial flutter. In the assessment of the patient comorbidity profile, antiarrhythmic drug onset of action and side effect profile versus the need for a physician with experience in sedation, or anaesthetics support for electrical cardioversion are key aspects when choosing the cardioversion method.
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial completion:  Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) -  May 30, 2024   
    P4,  N=16, Completed, 
    In the assessment of the patient comorbidity profile, antiarrhythmic drug onset of action and side effect profile versus the need for a physician with experience in sedation, or anaesthetics support for electrical cardioversion are key aspects when choosing the cardioversion method. Active, not recruiting --> Completed
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Enrollment closed, Enrollment change:  Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) -  Mar 19, 2024   
    P4,  N=16, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=40 --> 16
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial completion date, Trial primary completion date:  Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) -  Feb 15, 2024   
    P4,  N=40, Recruiting, 
    Besides, the duration of AF was found as a risk factor for early postoperative recurrence, while ibutilide administration for successful conversion had no influence on predicting postoperative recurrence and had no influence on postoperative maintenance time of sinus rhythm. Trial completion date: Feb 2024 --> Jul 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
  • ||||||||||  Corvert (ibutilide) / Pfizer
    WOLFF-PARKINSON-WHITE SYNDROME AND ATRIAL FIBRILLATION IN AN OTHERWISE HEALTHY YOUNG MALE (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_300;    
    Prompt recognition of the WPW and AF via ECG is important in the proper treatment of this arrhythmia (usually with class IA, IC, or III antiarrhythmics) to prevent degeneration to VF. We share this case to raise awareness of the detrimental effects of misdiagnosis and mistreatment of a rare yet serious condition.
  • ||||||||||  Journal:  Treatment of atrial fibrillation. (Pubmed Central) -  Jan 9, 2024   
    In our experimental model, a combination of flecainide and ibutilide significantly improves cardioversion and prevents the recurrence of AF compared with monotherapies with little to no risk for the development of long-QT-mediated ventricular proarrhythmia. No abstract available
  • ||||||||||  Corvert (ibutilide) / Pfizer, Brinavess (vernakalant) / Merck (MSD), Correvio
    Journal:  Pharmacological cardioversion of atrial fibrillation: practical considerations. (Pubmed Central) -  Aug 25, 2023   
    Given the risk of ventricular proarrhythmia of AAD, safety should always prevail over the enticing possibility of rhythm conversion. The present review aims to provide a comprehensible summary of proper qualification for PC, selection of suitable AAD and state-of-the-art periprocedural management of patients with recent-onset AF.
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial primary completion date:  Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) -  Jul 3, 2023   
    P4,  N=83, Recruiting, 
    The incidence of side effects must be taken into account in the choice of antiarrhythmic in clinical practice. Trial primary completion date: Oct 2024 --> Jan 2025
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial primary completion date:  Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) -  Jul 3, 2023   
    P4,  N=40, Recruiting, 
    Trial primary completion date: Oct 2024 --> Jan 2025 Trial primary completion date: Sep 2023 --> Jan 2024
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial primary completion date:  Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) -  Mar 7, 2023   
    P4,  N=40, Recruiting, 
    Additionally, we found that females responded to ibutilide better than males, regardless of whether they were pretreated with magnesium sulfate. Trial primary completion date: Mar 2023 --> Sep 2023
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Journal:  A non-targeted metabolomics study on serum of occupational people exposed with nanometer titanium dioxide particles (TiO(2)-NPs) (Pubmed Central) -  Dec 14, 2022   
    46 different metabolites were screened out by P1, mainly including glycerides, sphingomyelin, glycerophospholipid, fatty acyl, etc.; By ROC analysis to determine 3-hydroxy-4, 5-dimethyl-2 (5H) - furanone, 4-aminobiphenyl, heptanoylcarnitine, Hexadecanedioic acid mono-L-carnitine ester, Ibutilide, LysoPA (18∶1 (9Z) /0∶0), LysoPC (18∶0), PC (16∶0/16∶0), PC (16∶0/20: 4 (5Z, 8Z, 11Z, 14Z) ), PC (P-18∶1 (9Z) /P-18∶1 (9Z) ) 10 candidate biomarkers; involving changes in 4 metabolic pathways, namely glycerophospholipid metabolism, sphingolipid metabolism, phenylalanine, tyrosine and tryptophan acid biosynthesis, linoleic acid metabolism. Occupational exposure to TiO(2)-NPs has a significant impact on serum metabolic profiles.
  • ||||||||||  Corvert (ibutilide) / Pfizer, Halfan (halofantrine) / GSK
    Journal, Adverse events:  Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system. (Pubmed Central) -  Nov 16, 2022   
    According to the disproportionality analysis, the top five drugs with the highest ROR and PRR were tolazoline (ROR 1615.11, 95% confidence interval [CI] 455.59-5725.75, PRR 969.46, χ 2960.10), levomethadyl (ROR 1211.01, 95% CI 302.75-4844.04, PRR 807.67, χ 1677.03), ibutilide (ROR 1118.74, 95% CI 425.00-2944.91, PRR 765.77, χ 3845.27), halofantrine (ROR 660.55, 95% CI 184.21-2368.69, PRR 519.22, χ 1076.31), and isoproterenol (ROR 352.20, 95% CI 227.19-546.00, PRR 307.82, χ 6692.53)...Notably, potential risks are of great importance and should be closely monitored in clinical practice. Also, further research is needed to investigate the association between these drugs and TdP.
  • ||||||||||  Corvert (ibutilide) / Pfizer, Brinavess (vernakalant) / Merck (MSD), Correvio
    Journal:  Body Weight Counts-Cardioversion with Vernakalant or Ibutilide at the Emergency Department. (Pubmed Central) -  Sep 13, 2022   
    Both, the Vernakalant and Ibutilide treatment arms showed comparable rates of treatment success in pharmacotherapeutic cardioversion of AF and AFL. Of utmost importance, we observed that the fixed dose of Ibutilide-as compared to the weight-adapted dose of Vernakalant-showed a reduced treatment success with increasing body weight.
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Journal:  Response to ibutilide and the long-term outcome after catheter ablation for non-paroxysmal atrial fibrillation. (Pubmed Central) -  Aug 6, 2022   
    These haemodynamic side effects may constitute a second component of their arrhythmic profile, acting as a trigger alongside their intrinsic arrhythmogenic electrophysiological properties. In patients whose atrial fibrillation persisted after pulmonary vein isolation, the response to ibutilide administration could predict the recurrence of atrial arrhythmias after catheter ablation, which may be useful for risk stratification for recurrence of atrial fibrillation and individualised management of atrial fibrillation.
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial completion date, Trial primary completion date:  Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) -  Aug 5, 2022   
    P4,  N=40, Recruiting, 
    In patients whose atrial fibrillation persisted after pulmonary vein isolation, the response to ibutilide administration could predict the recurrence of atrial arrhythmias after catheter ablation, which may be useful for risk stratification for recurrence of atrial fibrillation and individualised management of atrial fibrillation. Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Mar 2023
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial completion date, Trial primary completion date:  Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) -  Jul 21, 2022   
    P4,  N=83, Recruiting, 
    Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Mar 2023 Trial completion date: Aug 2025 --> Apr 2025 | Trial primary completion date: Apr 2025 --> Oct 2024
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial completion date, Trial primary completion date:  Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) -  Jun 10, 2022   
    P4,  N=40, Recruiting, 
    Randomized trials are warranted to confirm our findings. Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial primary completion date:  Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) -  May 25, 2022   
    P4,  N=83, Recruiting, 
    Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Trial primary completion date: Aug 2025 --> Apr 2025
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Journal:  A High-throughput Assay to Identify Drugs that can Treat Long QT Syndrome Caused by Trafficking-deficient K11.1 (hERG) Variants. (Pubmed Central) -  Apr 30, 2022   
    To validate the optimized trafficking assay, we carried out a pilot screen that identified three drugs (ibutilide, azaperone, and azelastine) that increase K11.1 trafficking...Significance Statement This paper involves the development of an HTS method to rapidly discover new drugs that increase membrane trafficking of LQTS K11.1 variants. Two key aspects that improved the resolving power of the assay and could be transferable to other ion channel trafficking related assays include genetic modification and channel activation.
  • ||||||||||  Onoact (landiolol) / Ono Pharma, Corvert (ibutilide) / Pfizer
    Clinical, Review, Journal:  Management of new onset atrial fibrillation in critically unwell adult patients: a systematic review and narrative synthesis. (Pubmed Central) -  Apr 27, 2022   
    Future RCTs comparing individual anti-arrhythmic agents, in particular magnesium, amiodarone, and β-antagonists, and studying the role of anticoagulation in critically unwell patients are required. There is also an urgent need for a core outcome dataset for studies of new onset atrial fibrillation to allow comparisons between different anti-arrhythmic strategies.
  • ||||||||||  Corvert (ibutilide) / Pfizer, Brinavess (vernakalant) / Merck (MSD), Correvio
    Review, Journal:  Cardioversion of recent-onset atrial fibrillation using intravenous antiarrhythmics: A European Perspective. (Pubmed Central) -  Feb 22, 2022   
    Intravenous new class III agents as dofetilide and ibutilide have high and rapid efficacy in converting AF to sinus rhythm but require strict surveillance with ECG monitoring during and after intravenous administration because the potential risk of QT prolongation and Torsades de Pointes which can be prevented and properly managed. Vernakalant, a partial atrial selective was shown to have a high success rate and to be safe in real life use.
  • ||||||||||  Corvert (ibutilide) / Pfizer
    CARDIOVERSION BY POTHOLE (Poster Hall_Hall C) -  Jan 28, 2022 - Abstract #ACC2022ACC_2701;    
    Careful inspection of the EKG for pre-excitation is crucial. AV nodal blocking agents should be avoided due to possible deterioration to ventricular fibrillation.
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Enrollment open:  Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) -  Oct 27, 2021   
    P4,  N=83, Recruiting, 
    TdP is a potentially serious adverse event that requires careful monitoring. Not yet recruiting --> Recruiting
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial initiation date:  Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) -  Aug 25, 2021   
    P4,  N=83, Not yet recruiting, 
    Transdermal testosterone attenuates drug-induced lengthening of both early and late ventricular repolarization in older men. Initiation date: Jul 2021 --> Oct 2021
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Journal:  Low-Voltage Zones as the Atrial Fibrillation Substrates: Relationship With Initiation, Perpetuation, and Termination. (Pubmed Central) -  Aug 20, 2021   
    Terminable AF was defined as those that could be terminated into sinus rhythm within 1 h after ibutilide administration...Segmental LVZ% difference was initially observed in the anterior wall for patients with inducible AF, and the septum was further affected in those with sustainable AF, and the roof, posterior wall, and floor were finally affected in those with interminable AF. The associations between LVZ with AF initiation, perpetuation, and termination were different depending on its size and distribution.